Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

92 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nasal and blood transcriptomic pathways underpinning the clinical response to grass pollen immunotherapy.
Altman MC, Segnitz RM, Larson D, Jayavelu ND, Smith MT, Patel S, Scadding GW, Qin T, Sanda S, Steveling E, Eifan AO, Penagos M, Jacobson MR, Parkin RV, Shamji MH, Togias A, Durham SR. Altman MC, et al. Among authors: sanda s. J Allergy Clin Immunol. 2023 Nov;152(5):1247-1260. doi: 10.1016/j.jaci.2023.06.025. Epub 2023 Jul 15. J Allergy Clin Immunol. 2023. PMID: 37460024 Clinical Trial.
Distinct trajectories distinguish antigen-specific T cells in peanut-allergic individuals undergoing oral immunotherapy.
Calise J, DeBerg H, Garabatos N, Khosa S, Bajzik V, Calderon LB, Aldridge K, Rosasco M, Ferslew BC, Zhu T, Smulders R, Wheatley LM, Laidlaw TM, Qin T, Chichili GR, Adelman DC, Farrington M, Robinson D, Jeong D, Jones SM, Sanda S, Larson D, Kwok WW, Baloh C, Nepom GT, Wambre E; IMPACT. Calise J, et al. Among authors: sanda s. J Allergy Clin Immunol. 2023 Jul;152(1):155-166.e9. doi: 10.1016/j.jaci.2023.03.020. Epub 2023 Mar 30. J Allergy Clin Immunol. 2023. PMID: 37003475
Epidemiological situation of SARS-CoV-2 infection in Douala, the most populated and highly heterogeneous town of Cameroon: a post-vaccination update.
Moguem Soubgui AF, Embolo Enyegue EL, Kojom Foko LP, Ndeme Mboussi WS, Deutou Hogoue G, Mbougang SP, Sanda SM, Fotso Chidjou IU, Fotso VF, Nzogang Tchonet SA, Medi Sike C, Koanga Mogtomo ML. Moguem Soubgui AF, et al. Among authors: sanda sm. Acta Trop. 2023 May;241:106864. doi: 10.1016/j.actatropica.2023.106864. Epub 2023 Feb 26. Acta Trop. 2023. PMID: 36849093 Free PMC article.
HLA-associated outcomes in peanut oral immunotherapy trials identify mechanistic and clinical determinants of therapeutic success.
Kanchan K, Shankar G, Huffaker MF, Bahnson HT, Chinthrajah RS, Sanda S, Manohar M, Ling H, Paschall JE, Toit GD, Ruczinski I, Togias A, Lack G, Nadeau KC, Jones SM, Nepom GT, Mathias RA. Kanchan K, et al. Among authors: sanda s. Front Immunol. 2022 Nov 18;13:941839. doi: 10.3389/fimmu.2022.941839. eCollection 2022. Front Immunol. 2022. PMID: 36466872 Free PMC article.
Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: A randomized controlled trial.
Corren J, Larson D, Altman MC, Segnitz RM, Avila PC, Greenberger PA, Baroody F, Moss MH, Nelson H, Burbank AJ, Hernandez ML, Peden D, Saini S, Tilles S, Hussain I, Whitehouse D, Qin T, Villarreal M, Sever M, Wheatley LM, Nepom GT, Sanda S; Immune Tolerance Network ITN057AD CATNIP Study Team. Corren J, et al. Among authors: sanda s. J Allergy Clin Immunol. 2023 Jan;151(1):192-201. doi: 10.1016/j.jaci.2022.08.029. Epub 2022 Oct 9. J Allergy Clin Immunol. 2023. PMID: 36223848 Clinical Trial.
Interpretation of Bone Mineral Density Z-Scores by Dual-Energy X-Ray Absorptiometry in Transgender and Gender Diverse Youth Prior to Gender-Affirming Medical Therapy.
Lee JY, Fan B, Montenegro G, Long RK, Sanda S, Capodanno G, Schafer AL, Burghardt AJ, Rosenthal SM, Fung EB. Lee JY, et al. Among authors: sanda s. J Clin Densitom. 2022 Oct-Dec;25(4):559-568. doi: 10.1016/j.jocd.2022.07.002. Epub 2022 Jul 13. J Clin Densitom. 2022. PMID: 35941040 Free PMC article. No abstract available.
Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study.
Jones SM, Kim EH, Nadeau KC, Nowak-Wegrzyn A, Wood RA, Sampson HA, Scurlock AM, Chinthrajah S, Wang J, Pesek RD, Sindher SB, Kulis M, Johnson J, Spain K, Babineau DC, Chin H, Laurienzo-Panza J, Yan R, Larson D, Qin T, Whitehouse D, Sever ML, Sanda S, Plaut M, Wheatley LM, Burks AW; Immune Tolerance Network. Jones SM, et al. Among authors: sanda s. Lancet. 2022 Jan 22;399(10322):359-371. doi: 10.1016/S0140-6736(21)02390-4. Lancet. 2022. PMID: 35065784 Free PMC article. Clinical Trial.
92 results